Press coverage about USANA Health Sciences (NYSE:USNA) has been trending somewhat positive recently, according to Accern. The research group rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. USANA Health Sciences earned a daily sentiment score of 0.12 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 44.1074274892541 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Several brokerages have commented on USNA. Pivotal Research boosted their price objective on shares of USANA Health Sciences from $70.00 to $80.00 and gave the company a “buy” rating in a research report on Wednesday, October 25th. BidaskClub downgraded shares of USANA Health Sciences from a “hold” rating to a “sell” rating in a research report on Thursday, November 2nd.
USANA Health Sciences (NYSE:USNA) opened at $74.15 on Tuesday. The stock has a market cap of $1,780.00, a price-to-earnings ratio of 20.43 and a beta of 1.06. USANA Health Sciences has a 1-year low of $52.55 and a 1-year high of $76.15.
USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings results on Tuesday, October 24th. The company reported $1.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.91 by $0.11. The company had revenue of $261.77 million during the quarter, compared to the consensus estimate of $259.52 million. USANA Health Sciences had a net margin of 8.79% and a return on equity of 26.38%. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period in the prior year, the business earned $2.40 earnings per share. equities research analysts expect that USANA Health Sciences will post 3.7 EPS for the current fiscal year.
In other news, major shareholder Global Ltd Gull sold 93,443 shares of the company’s stock in a transaction on Monday, October 30th. The shares were sold at an average price of $67.08, for a total transaction of $6,268,156.44. Following the completion of the transaction, the insider now directly owns 12,089,267 shares in the company, valued at $810,948,030.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gilbert A. Fuller sold 1,710 shares of the company’s stock in a transaction on Thursday, October 26th. The stock was sold at an average price of $67.01, for a total transaction of $114,587.10. Following the transaction, the director now owns 1,710 shares of the company’s stock, valued at $114,587.10. The disclosure for this sale can be found here. Insiders have sold 623,752 shares of company stock valued at $41,411,372 over the last quarter. Company insiders own 53.20% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “USANA Health Sciences (USNA) Receiving Somewhat Favorable Press Coverage, Analysis Shows” was first reported by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://transcriptdaily.com/2018/01/09/usana-health-sciences-usna-receiving-somewhat-favorable-press-coverage-analysis-shows.html.
USANA Health Sciences Company Profile
USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.